Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Idiopathic Pulmonary Fibrosis, Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype, Systemic Sclerosis-associated Interstitial Lung Disease Age: Adult |
Dose: Oral – 150 mg Frequency: twice daily Note: Maximum: 300 mg daily |
|
Indication: Locally advanced non-small cell lung carcinoma, Locally recurrent non-small cell lung carcinoma, Metastatic non-small cell lung carcinoma Age: Adult Condition: In combination with docetaxel |
Dose: Oral – 200 mg Frequency: twice daily on days 2 to 21 of a 21-day treatment cycle Note: Maximum: 400 mg daily |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Clinically significant, progressive fibrosing interstitial lung diseases and systemic sclerosis-associated interstitial lung disease Age: 6 to 17 years |
Dose: Oral – 50 mg Frequency: Twice daily Note: Route: Oral |
|
Indication: Clinically significant, progressive fibrosing interstitial lung diseases and systemic sclerosis-associated interstitial lung disease Age: 6 to 17 years |
Dose: Oral – 75 mg Frequency: Twice daily Note: Route: Oral |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Mild-to-moderate renal impairment |
Dose: Not specified Note: No dosage adjustment required |
|
Condition: Severe renal impairment (Creatinine Clearance less than 30 mL/min) or End Stage Renal Disease |
Dose: Not specified Note: Not studied |
Administration
- Take with food
- Swallow capsules whole
Side Effect
- Diarrhea (62%)
- Nausea (24%)
- Abdominal pain (15%)
- Elevated liver enzymes (14%)
- Vomiting (12%)
- Decreased appetite (11%)
- Diarrhea (76%)
- Nausea (32%)
- Vomiting (25%)
- Skin ulcer (18%)
- Abdominal pain (18%)
- Liver enzyme elevation (13%)
- Decreased weight (12%)
- Fatigue (11%)
- Idiopathic pulmonary fibrosis
- Decreased weight (10%)
- Bleeding events (10%)
- Headache (8%)
- Hypertension (5%)
- Arterial thromboembolic events (2.5%)
- Myocardial infarction (1.5%)
- Bronchitis (1.5%)
- Hypothyroidism (1.1%)
- Decreased appetite (9%)
- Headache (9%)
- Pyrexia (6%)
- Back pain (6%)
- Dizziness (6%)
- Hypertension (5%)
- Pneumonia (0.7%) Lung neoplasm malignant (0.3%) Gastrointestinal perforation (0.3%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Corticosteroids (Prednisone, Prednisolone, Methylprednisolone, Dexamethasone, Hydrocortisone), NSAIDs (Ibuprofen, Naproxen, Diclofenac, Celecoxib, Meloxicam, Indomethacin, Piroxicam, Ketorolac)
|
Increased risk of gastrointestinal adverse effect
|
|
Strong P-gp inhibitors (e.g. ketoconazole, erythromycin, ciclosporine)
|
Increased plasma concentration
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store in a cool and dry place, protected from light. Do not store above 25°C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.